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GUIDELINES
Second-line or Subsequent Systemic Therapy for Recurrent
or Progressive Non-Small Cell Lung Cancer: A Systematic
Review and Practice Guideline
J. Noble, MD,* P.M. Ellis, MBBS, PhD,† J.A. Mackay, MA, MSc,‡ W.K. Evans, MD,† and
the Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care§
Purpose: This clinical practice guideline, based on a systematic
review, evaluates second-line or subsequent therapy for patients
with recurrent or progressive non-small cell lung cancer.
Methods: Relevant randomized trials and meta-analyses were iden-
tified through a systematic search of the literature. External feedback
was obtained from practitioners in Ontario, and the guideline was
approved by the provincial Lung Cancer Disease Site Group.
Results: Twenty-four randomized trials met the eligibility criteria.
Two phase III trials demonstrated a significant benefit in overall
survival and quality of life (QOL) for single-agent docetaxel. A
pooled analysis comparing docetaxel administered weekly versus
three-weekly found similar survival between the schedules and a
non-significant reduction in febrile neutropenia for the weekly
regimen. One phase III trial found that single-agent pemetrexed
provided similar survival and QOL, compared to docetaxel. Another
phase III trial demonstrated that oral topotecan was non-inferior to
docetaxel for one-year survival rate, although QOL significantly
favored docetaxel over topotecan. Docetaxel-based and other com-
bination chemotherapy regimens have not been shown to be superior
to single-agent docetaxel. One phase III trial revealed a statistically
significant survival and QOL benefit for erlotinib over placebo for
patients who were not eligible for further chemotherapy. Modest
tumor response rates and symptom control have been demonstrated
for gefitinib; however, a statistically significant survival benefit has
not been established for gefitinib over placebo.
Conclusion: Second-line or subsequent therapy with single-agent
docetaxel, pemetrexed, or erlotinib offers patients a significant
survival and QOL advantage.
Key Words: non-small cell lung cancer, recurrence, retreatment,
systematic review.
(J Thorac Oncol. 2006;1: 1042–1058)
Lung cancer remains the leading cause of cancer deaths inthe United States, with an estimated 174,000 Americans
expected to be diagnosed and 162,000 expected to die of the
disease in 2006.1 Non-small cell lung cancer (NSCLC) ac-
counts for approximately 80% of lung cancer diagnoses in the
United States.2 The great majority of patient deaths from
NSCLC occur in the setting of advanced disease, which is
commonly present at initial presentation or at relapse. The
five-year survival for stages IIIB and IV NSCLC are typically
less than 5%.3
Standard first-line systemic therapy for advanced NSCLC
is platinum-based doublet chemotherapy. In clinical trials, ap-
proximately 30–40% of patients relapsing or progressing after
first-line therapy go on to receive second-line chemotherapy.4–7
In 2001, the Lung Cancer Disease Site Group (Lung DSG)
recommended single-agent docetaxel at a dose of 75 mg/m2
every three weeks as second-line treatment for suitable patients
with advanced or metastatic NSCLC who progressed following
platinum-based combination chemotherapy.8 Over the last few
years, a number of potential alternatives to single-agent do-
cetaxel have emerged for second-line and subsequent systemic
therapy of NSCLC, including single-agent pemetrexed, single-
agent topotecan, docetaxel-based and other combination chemo-
therapy regimens, and the epidermal growth factor receptor
inhibitors, gefitinib and erlotinib. At the same time, efforts have
been made to improve the tolerability of single-agent docetaxel,
by modifying the dose and schedule of treatment.
In light of recent developments, the Lung DSG decided
to develop an evidence-based practice guideline to address
the following questions: 1) What are the survival and/or
quality of life (QOL) benefits of systemic therapy compared
with best supportive care (BSC) in the second-line and subse-
quent treatment of recurrent or progressive NSCLC? 2) Which
systemic therapy agent or combination of agents provide the
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greatest improvement in survival and/or QOL in the second-line
and subsequent treatment of recurrent or progressive disease? 3)
What are the optimal doses and schedules of different systemic
therapy agents in the second-line or subsequent treatment of
recurrent or progressive disease?
METHODS
This practice guideline was developed by Cancer Care
Ontario’s Program in Evidence-based Care (PEBC), using the
methods of the Practice Guidelines Development Cycle.9
This guideline is based on a systematic review and is intended
to promote evidence-based practice. This report has been
edited and condensed for publication. The unabridged version
is available on the PEBC section of the Cancer Care Ontario
Web site at http://www.cancercare.on.ca/.
Literature Search Strategy
Evidence was identified through a systematic search of
the databases MEDLINE (1996-November 2005), EMBASE
(1996-2005, week 53), and the Cochrane Library (2005, Issue
4). Search terms are detailed in Appendix A. Conference
proceedings from 2000 to 2005 of the American Society of
Clinical Oncology, the International Association for the
Study of Lung Cancer, the European Cancer Conference, and
the European Society for Medical Oncology and article ref-
erence lists were also searched.
Study Selection Criteria
Articles published as full reports or as abstracts were
included if they focused on second-line or subsequent sys-
temic therapy for recurrent or progressive NSCLC; reported
data on survival, QOL, tumor response rate, symptom con-
trol, or toxicity; and were randomized trials comparing dif-
ferent systemic therapy agents or regimens, or systemic
therapy with BSC or were randomized trials comparing
different doses and/or schedules of systemic therapy agents.
Trials that included a mix of untreated and previously treated
patients or included less than 50 patients per trial arm were
excluded. Trials published in a language other than English
were also not considered.
Synthesizing the Evidence
A pooled analysis of mortality data of weekly versus
three-weekly administration of second-line or subsequent
single-agent docetaxel was planned and conducted on six-
month survival data. Data were extrapolated from survival
curves independently by two researchers, and the average of
the two estimates was used. Data censored on the survival
curves were not accounted for, which may limit the reliability
of the results.10 A post-hoc meta-analysis was conducted to
explore the impact of a weekly versus three-weekly docetaxel
schedule on the incidence of grade 3/4 febrile neutropenia.
This analysis was based on the number of patients who
reported experiencing an event in each treatment arm com-
pared with the number of patients who were available for
toxicity evaluation. Where not provided, the latter number
was assumed to equal the number of patients randomized.
Trials were pooled using Review Manager 4.2.7, which is
available through the Cochrane Collaboration [Review Man-
ager (RevMan) [Computer program]. Version 4.2 for Win-
dows. Oxford (England): The Cochrane Collaboration, 2003].
Pooled results are expressed as a relative risk ratio with 95%
confidence intervals (CI) using the random effects model.
Relative risk1 indicates a benefit for weekly administration
of docetaxel and relative risk 1 suggests a benefit for
three-weekly administration. Sensitivity analyses were also
conducted to explore the impact of including data from
abstract reports.
External Review and Approval
Draft recommendations were sent to practitioners in
Ontario, Canada for external review. The external review is a
mailed survey consisting of items that address the quality of
the draft report and recommendations and whether the draft
recommendations should serve as a practice guideline. The
provincial Lung DSG and the PEBC Report Approval Panel
also reviewed and approved the guideline.
RESULTS
Literature Search Results
Twenty-four individual randomized trials met the eli-
gibility criteria for this systematic review. Multiple reports of
the same study were included if each report provided addi-
tional relevant data. Data from slide presentations associated
with abstracts were included if the presentations were pub-
licly available on meeting Web sites. The majority of ran-
domized trials enrolled a mixture of patients with regard to
the number of lines of systemic therapy previously received.
Although most of the trials described the patient sample in
these terms, few reported outcomes specifically by line of
therapy.
Outcomes
Chemotherapy
Single-Agent Docetaxel Compared with BSC or Another
Single Agent
Four randomized phase III trials compared single-agent
docetaxel with either BSC or another single-agent chemo-
therapy as second-line or subsequent therapy for relapsed or
progressive NSCLC11–18 (Table 1). One trial was published in
abstract form only and provided limited data on which to
assess the trial quality.17,18 All trials were described as ran-
domized, multicenter, and industry-supported and were strat-
ified by performance status (PS); however, the method of
randomization was not described in detail, and none reported
blinding of treatment assignment. Survival was the primary
outcome, with survival analyses conducted on an intent-to-
treat basis. Each trial also included QOL as an endpoint. One
trial did not report the pre-determined required sample size,
and the estimated power of the trial was based on a non-
inferiority hypothesis that the survival time for the experi-
mental treatment would not be greater than 10% worse than
the reference treatment arm.15
A randomized phase III trial conducted by Shepherd et
al (TAX 317) compared docetaxel with BSC.11 The trial was
initially designed to compare docetaxel at a dose of 100
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mg/m2 three-weekly (D100); however, an excess of treat-
ment-related deaths led to a dose reduction to 75 mg/m2
(D75) for patients enrolled in the second half of the trial.
Treatment was continued until disease progression or unac-
ceptable toxicity. Comparison of the survival outcomes re-
vealed a significant benefit for treatment for the combined
docetaxel arms over BSC, and for D75 versus BSC75, but no
difference in survival for D100 versus BSC100. Median
survival for D75 was 7.5 months compared to 4.6 months for
BSC (p  0.01 log rank). This survival benefit was seen
despite a low overall tumor response rate (RR) of 5.8% for
the combined docetaxel arms. The overall stable disease rate
was 43% for the combined docetaxel arms. The incidence of
febrile neutropenia was significantly higher for D100 than for
D75, with grade 3/4 in 22% of patients (including three
deaths) versus 2% (with no deaths), respectively. However,
non-hematologic toxicities were similar for both treatment
groups. The median number of chemotherapy cycles deliv-
ered was significantly lower for D100 than for D75, at two
versus four cycles.
The QOL analysis for the Shepherd et al (TAX 317)
trial was reported separately by Dancey et al.12 The compar-
ison of QOL changes revealed a significant difference in
mean patient-rated pain scores, favoring the combined do-
cetaxel treatment arms over BSC p  0.005), and trends in
favor of treatment for observer-rated scales for fatigue and
pain. In separate comparisons of D100 versus BSC100 and
D75 versus BSC75, D100 (but not D75) showed significant
benefits over BSC in mean patient-rated pain scores p 
0.003), and trends in favor of docetaxel for observer-rated
total Lung Cancer Symptom Scale (LCSS) score p  0.094),
appetite p  0.098), and fatigue p  0.092).
In the randomized phase III trial by Fossella et al (TAX
320), two dose levels of docetaxel, 100 mg/m2 and 75 mg/m2
administered three-weekly (D100 and D75), were compared
with a control arm of vinorelbine or ifosfamide (V/I), with the
control treatment chosen by the investigator.13 Treatment was
continued for six or more cycles in patients with response or
stable disease in the absence of unacceptable toxicity. Com-
parison of each docetaxel arm versus V/I showed no statis-
tically significant difference in overall survival between the
treatment groups. However, comparison of one-year survival
rates (post-hoc) revealed a significant benefit for D75 over
V/I (32% versus 19%, p  0.025, chi-square). Once again,
the RR with each treatment was relatively modest, although
significantly higher for both docetaxel arms than for V/I. The
stable disease rates were 33% for D100 and 36% for D75,
compared to 31% for V/I. The median number of cycles of
chemotherapy administered was three in both docetaxel arms,
three in the vinorelbine arm, and two in the ifosfamide arm.
Approximately one-third of patients received additional che-
motherapy following study treatment (including 15% of pa-
tients in the control arm who subsequently received do-
cetaxel). In order to explore the potential impact of crossover
treatment on survival, comparisons were made both with
(post-hoc) and without censoring at the time of additional
post-study treatment. After censoring, the overall survival
difference remained non-significant for D100 versus V/I p 
0.13 log rank), and for D75 versus V/I p  0.12 log rank),
although the one-year survival rates for both docetaxel arms
became statistically superior to the control arm (32% for
D100 and D75 versus 10% for V/I, p  0.001 chi-square and
p  0.002 chi-square, for D100 and D75 arms, respectively).
Prior treatment with paclitaxel did not appear to influence
survival or RR with docetaxel. The incidence of febrile
neutropenia was considerably higher in the docetaxel arms
but was not associated with an excess of treatment-related
deaths in the D100 arm, as seen in the TAX 317 trial.11 Grade
3/4 non-hematologic toxicities were infrequent and occurred
with similar incidence in all three treatment groups.
Results of the QOL analyses from the Fossella et al (TAX
320) trial have yet to be fully reported. In an abstract report,
Miller et al reported a benefit for docetaxel over V/I, particularly
in the D100 arm, on a number of QOL scores from the LCSS,
including patient-rated total score, fatigue, and total symptom-
atic distress, and observer-related total score and pain.14
The randomized phase III trial by Hanna et al (JMEI),
was designed to test for non-inferiority with respect to sur-
vival of pemetrexed at a dose of 500 mg/m2 versus docetaxel
at 75 mg/m2, each administered on a three-weekly schedule
as second-line treatment.15 Patients assigned to pemetrexed
also received vitamin supplementation with folic acid plus
vitamin B12 for the duration of treatment. Treatment was
continued until disease progression or unacceptable toxicity.
The median number of cycles of chemotherapy administered
was four in both groups. Median follow-up for all patients
was 7.5 months, and 71.6% of patients had died by the time
of the analysis.
The primary test for non-inferiority required that sur-
vival with pemetrexed be 10% worse than with docetaxel
(corresponding to a true hazard ratio [HR] of 0.83 and an
upper 95% confidence limit [CI] of 1.11 for pemetrexed
over docetaxel). This test for non-inferiority was not met (HR
0.99; 95% CI 0.82 to 1.2; non-inferiority p  0.226). How-
ever, a second pre-planned test of non-inferiority (percent
retention method), which required that pemetrexed retain
50% of the survival benefit of docetaxel over BSC observed
in the Shepherd et al (TAX 317) trial,11 was statistically
significant (102% survival benefit retained with a lower 95%
confidence limit of 52%, p  0.047). In a multivariate
analysis, survival was also shown to be similar for both
treatment groups (HR 0.93; 95% CI 0.76–1.13; non-inferiority
p  0.051) after adjusting for variables associated with
increased survival (PS, disease stage, and time since last
chemotherapy).
Approximately 42% of patients received additional
chemotherapy following study treatment, including 47% of
patients in the pemetrexed arm (two thirds of whom received
docetaxel) and 37% in the docetaxel arm. In order to assess
the potential impact of treatment crossover on the test of
non-inferiority, an exploratory analysis was performed of
patients who went on to receive subsequent chemotherapy. In
that analysis, the median survival of pemetrexed patients who
subsequently received docetaxel (n  85, 9.6 months) ap-
peared to be no better than that of patients who received other
chemotherapy agents post-study (n  41, 10.6 months, p 
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0.219),15,16 arguing against a substantial impact of crossover
from pemetrexed to docetaxel on the survival analysis.
The incidence of febrile neutropenia, infections, and
hospitalizations due to neutropenic events was significantly
higher for docetaxel than for pemetrexed, but treatment-
related deaths and non-hematologic toxicities, occurred with
similar frequency in both arms. QOL assessments indicated
no significant differences between the treatment groups.
The randomized phase III trial by Ramlau et al, (387)
was designed to test the non-inferiority of oral topotecan at a
dose of 2.3 mg/m2/d on days 1-5 versus IV docetaxel at 75
mg/m2 on day 1, each administered on a three-weekly sched-
ule, as second-line therapy.17,18 Treatment was continued for
at least four cycles or until disease progression. The median
number of cycles of chemotherapy administered was four in
the docetaxel arm and three in the topotecan arm.
The test for non-inferiority, which required that the
one-year survival rate with topotecan be less than 10% worse
than with docetaxel, was met. The one-year survival for
topotecan was 25.1% compared to 28.7% for docetaxel,
corresponding to an absolute difference of 3.6% (95% CI
9.6% to 2.5%). The overall survival was not statistically
significant between treatment groups but showed a trend in
favor of docetaxel (HR 1.16; 95% CI 1.00–1.35, log-rank
p  0.057). Approximately 28% of patients received additional
chemotherapy following study treatment, including 31% of
patients in the topotecan arm and 25% in the docetaxel arm.17,18
The pattern of grade 3/4 toxicities differed by treatment
arm. The incidence of neutropenia and sepsis was higher for
docetaxel, whereas anemia and thrombocytopenia were more
frequent with topotecan. Grade 3/4 non-hematologic toxici-
ties were infrequent but included more frequent neuropathy
for docetaxel and a higher incidence of nausea for topotecan.
QOL assessments were significantly higher for the docetaxel
arm when compared to topotecan (p  0.0001, Wilcoxon
rank-sum test). The rate of change from baseline of individual
LCSS scores in the slope analysis also favored docetaxel,
although the only significant difference seen was for appetite,
which was perhaps attributable to pre-medication with dexa-
methasone.
Single-Agent Docetaxel - Dose and Schedule
Comparisons
Docetaxel administered at a dose of 75 mg/m2 every
three weeks is associated with a significant risk of both
hematologic and non-hematologic toxicities, including grade
3/4 neutropenia (40–67%), febrile neutropenia (2–13%), grade
3/4 asthenia (5–18%), and alopecia (35–38%).11,13,15,17,18 Phase
I testing of lower doses of docetaxel administered weekly for
six consecutive weeks on an eight-week cycle to patients with
advanced refractory cancer suggested a lower incidence of
grade 3/4 neutropenia and febrile neutropenia, and promising
overall tolerability.19
Four randomized trials, including three phase III and
one phase II trial, have compared three-weekly with weekly
administration of single-agent docetaxel as a second-line or
subsequent therapy for relapsed/progressive NSCLC20–24
(Table 2). One of the phase III trials20,21 was reported in
abstract form only and provided limited data on the trial
methods. None of the trials reported blinding of treatment
assignment. One phase III trial (DISTAL-01) described the
method of randomization and determined sample size based
on QOL as a primary endpoint.22 In the second phase III trial,
sample size was based upon a test of equivalence for surviv-
al.23 In the third phase III trial, the method of randomization
and basis for sample-size determination were unclear, al-
though survival was described as the primary endpoint.20,21
Stratification variables differed for each of the phase III trials;
however, two included stratification by PS.20–22 The phase II
trial was explicitly described as non-comparative for efficacy
outcomes and included a primary outcome of safety, specif-
ically the incidence of grade 3/4 neutropenia, febrile neutro-
penia, nausea/vomiting, and asthenia.24
There was no evidence of a significant difference in
median survival between the schedules in any of the trials. A
pooled analysis of survival data from the randomized trials of
weekly (33.3–40 mg/m2) versus three-weekly (75 mg/m2) do-
cetaxel schedules was performed. Six months was chosen as the
time-point for pooling survival data, because that was prior to
the weighted median survival calculated for all studies (6.3
months) and would, therefore, be expected to include data from
a reasonable number of patients for analysis. The meta-analysis,
shown in Figure 1, detected no significant survival differences
between the two treatment administration schedules at six
months (Relative Risk, 0.99; p  0.91) and no significant
heterogeneity of treatment effects across trials p  0.34).
None of the four trials comparing weekly with three-
weekly docetaxel administration reported a statistically sig-
nificant difference in response rate between the two treatment
schedules. Of the three trials that reported QOL out-
comes,22,23,25 only one provided detailed data. In that trial,22
the comparison of treatment groups showed no significant
difference in the mean change from baseline in global QOL at
three weeks. However, significant changes from baseline
were observed for the weekly schedule in several other QOL
measures, including better pain control p  0.04), cough p 
0.007), and alopecia (p  0.001) and worse diarrhea p 
0.01). The QOL response at 21 days also showed significant
differences for cough p  0.007) and alopecia (p  0.0001),
favoring the weekly arm. Using daily diary cards, no statis-
tically significant differences by treatment regimens were
observed for most symptoms, with the exception of pain,
which was consistently lower with the weekly schedule p 
0.04 overall, p  0.74 interaction test across time).22 The
other two trials found no significant difference in QOL
between treatment groups.23,25
Of the four trials comparing weekly with three-weekly
administration of docetaxel, the majority indicated a reduced
risk of neutropenia and febrile neutropenia for docetaxel
administered weekly versus three-weekly.20–24 A meta-anal-
ysis of the incidence of febrile neutropenia for weekly versus
three-weekly docetaxel schedules was conducted. The inci-
dence of grade 3/4 febrile neutropenia was greater in the
three-weekly arm, but the difference was not statistically
significant (Relative Risk, 0.29; p 0.07), with no significant
heterogeneity of treatment effect.
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An additional published randomized phase II trial com-
pared two different doses of docetaxel (100 mg/m2 versus 75
mg/m2), both administered every three weeks.26 Median survival
was similar for the two arms; however, an imbalance in the
proportion of patients with stage IV disease assigned to each
treatment group may have influenced these results. The inci-
dence of grade 3/4 neutropenia was higher with docetaxel 100
mg/m2 but did not result in more frequent febrile neutropenia.
Docetaxel-Based Combination Chemotherapy
Comparisons
Docetaxel-based combination chemotherapy regimens
have been compared to single agents or other combination
regimens as second-line or subsequent therapy for relapsed/
progressive disease in four randomized trials (three phase II
and one phase III)27–33 (Table 3). Two trials were reported in
abstract form only. One of the trials reported receiving
industry support.30 None reported blinding of treatment as-
signment or described the randomization process in detail,
and only one trial described the method used for sample size
estimation.27,28 The primary outcome was RR in two tri-
als29,30 and survival in two trials.27,28,31–33
A randomized phase III trial of the Japanese Clinical
Oncology Group (JCOG 0104), compared docetaxel plus gem-
citabine with single-agent docetaxel.27,28 Planned enrolment for
that study was 284 patients; however, accrual was halted pre-
maturely at 130 patients, after an unexpectedly high incidence of
interstitial lung disease (ILD) was observed in the combination
arm. Grade 2–4 pneumonitis was seen in 16.9% of patients
receiving docetaxel plus gemcitabine compared to 1.6% for
single-agent docetaxel, with fatal pneumonitis occurring in 4.6%
of patients in the combination arm. No baseline risk factor, other
than male gender, was identified that predicted for development
of ILD. No significant difference in survival, QOL, or RR was
observed between treatment arms.
Two randomized phase II trials compared docetaxel
alone with docetaxel plus irinotecan29 plus G-CSF.30 One
trial employed a “pick-the-winner” statistical design to deter-
mine which was the best treatment arm.30 This strategy is
intended to rank outcomes, and is not equivalent to a standard
statistical comparison.34 The RRs were not significantly dif-
ferent across treatment arms in one trial p 0.36),29 although
single-agent docetaxel was ranked the “winner,” based upon
a higher RR in the second trial.30 No statistically significant
treatment differences in survival were observed in either trial;
however, the trials were not powered or designed to compare
survival.29,30
An additional randomized phase II trial by Lilenbaum
et al compared a docetaxel-based combination regimen with
either a single agent or another combination regimen.31–33
This trial employed a 2 2 design to compare irinotecan plus
docetaxel or gemcitabine, both with and without celecoxib.
No statistical comparisons were reported for this study, the
results of which are summarized in Table 3.
Combination Chemotherapy Without Docetaxel
Two small randomized phase II trials compared a non-
docetaxel-based combination chemotherapy regimen with sin-
gle-agent chemotherapy as second-line or subsequent therapy
for relapsed/progressive NSCLC35,36 (Table 4). Both trials com-
pared an irinotecan-based combination regimen with a single
FIGURE 1. Meta-analysis of Six-Month Survival for Weekly versus Three-Weekly Administration of
Single-Agent Docetaxel.
Abbreviations: CI  confidence interval, n  number of deaths,
N  number of patients, RR  Relative Risk.
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agent and determined the sample size by the primary endpoint of
survival with 90% power to detect a significant difference, and
one reported the method of randomization.35 Neither explicitly
reported the proportion of patients included in the analyses.
The Hellenic Oncology Research Group (HORG) com-
pared irinotecan plus gemcitabine versus single-agent irinote-
can.35 The RR for the combination regimen was superior, but
this did not translate into a significant survival benefit. The
combination treatment demonstrated significant superiority over
the single agent for several QOL parameters, including “general
mood today” p  0.014), cough p  0.033), and “intensity of
symptoms” p  0.034), although limited information was pro-
vided on the QOL analyses. A second trial by the HORG
compared cisplatin plus irinotecan versus single-agent cispla-
tin.36 The RR for the combination was also superior but did not
translate into improved median or one-year survival.
Novel Systemic Agents
Epidermal Growth Factor Receptor Inhibitors (EGFR-I)
A number of growth-factor-receptor-targeted agents
have been tested in the second-line or subsequent therapy of
relapsed/progressive NSCLC. These include two agents for
which randomized data are currently available. Both agents
are oral formulation, small-molecule receptor tyrosine kinase
inhibitors targeting the EGFR, namely, erlotinib (Tarceva®)
and gefitinib (Iressa®).
Two double-blind randomized phase III trials have
compared gefitinib or erlotinib with placebo.37,38 Both
trials involved multiple centers and enrolled patients in-
ternationally. Two published randomized phase II trials,
one performed in the U.S.39 and the other multination-
ally,40 evaluated different daily doses of gefitinib. One
randomized phase II trial, performed in Europe evaluated
TABLE 3. Trials of Docetaxel-Based Combination Chemotherapy
Reference Treatment Na
% Patientsb
Response Rate
(CRPR)d
Survival
Treatment
Line 2nd/
3rd/4th
PSc
0–1/2
Median, Months
(95% CI)
1-year
(95% CI) Overall
Randomized phase III trials
Takeda
2004e
(27,28)
Docetaxel 65 100/0/0 100/0 6.7% 10.1 (7.4–12.6) 41.9% (29.0–54.9) HR 0.9195% CI,
0.59–1.41 p 
0.68 log rank
Docetaxel 
Gemcitabine
65 100/0/0 100/0 7.0% 10.2 (6.5–14.7) 45.6% (33.1–58.1)
p  0.94
Randomized phase II trials
Pectasides
2005 (29)
Docetaxel 65 100/0/0 88/12 14% 6.4 (0.1–21.2) 34% p  0.49 log rank
Docetaxel 
Irinotecan
65 100/0/0 84/16 20% 6.5 (0.4–22.2) 37%
p  0.36 p  0.72
Wachters
2005 (30)
Docetaxel 56 NR 88/13 16% 7.4 (5.8–9.2) 26% p  0.69 log rank
Docetaxel 
Irinotecan 
G-CSF
52 96/4 10% 6.2 (1.8–10.6) 30%
Lilenbaum
2005e
(31–33)
Irinotecan 
Docetaxel /
Celecoxib (ID)
69 100/0/0 100/0 3% 6.4 21% NR
Irinotecan 
Gemcitabine /
Celecoxib (IG)
64 100/0/0 99/1 6% 8.9 40%
Celecoxib  ID
or IG (Cbx)
67 100/0/0 99/1 3% 6.3 24%
No Celecoxib 
ID or IG
(Cbx)
66 100/0/0 100/0 6% 9.2 36%
Abbreviations: CI  confidence interval, CR  complete response, G-CSF  granulocyte-colony stimulating factor, HR  hazard ratio, N  number of patients, NR  not
reported, PR  partial response, PS  performance status.
a This column reports the number of patients randomized or randomized and eligible unless otherwise indicated.
b Where reported, trials allowed for the inclusion of patients with CNS metastases which were stable and/or asymptomatic (30–33).
c Based on the Eastern Cooperative Oncology Group scale (27–33).
d Basis for calculation of response rate is randomized or eligible patients (29,30), 133 patients receiving at least one treatment (31–33), or 117 treated and eligible patients with
measurable lesions (27,28).
e Abstract.
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docetaxel alongside gefitinib.41,42 All five of these trials,
summarized in Table 5, received industry support. A
detailed description of the method of randomization was
lacking for several of the trials, although three specified
that randomization was performed centrally.37,38,40 Four
trials described the basis for the estimation of trial sample
size and met their target accrual.37–40 The randomized
phase II trials were not designed to compare outcomes
between treatment groups.39–42 For grade 3/4 toxicity data,
please see Appendix B.
Single-Agent Erlotinib Compared with BSC
A double-blind randomized phase III trial, conducted
by the National Cancer Institute of Canada Clinical Trials
Group (BR.21), assigned patients in a 2:1 ratio to erlotinib at
a dose of 150 mg daily or placebo.38 Eligible patients had to
have received one or two prior chemotherapy regimens and
be unsuitable for further chemotherapy. Treatment was con-
tinued until disease progression or unacceptable toxicity. The
study was initially powered to detect a 50% improvement in
median survival. However, the sample size was adjusted
before analysis, to provide power to detect a 33% improve-
ment in median survival.43 The collection of tumor samples
for tissue banking and correlative studies was optional.
The comparison of survival outcomes revealed a sig-
nificant survival benefit for erlotinib over placebo, after
adjustment for stratification factors (except center) and EGFR
status. The difference in RR was also statistically significant.
Analysis of the clinical predictors of response to erlotinib sug-
gested a higher response rate for patients of female gender,
Asian ethnicity, adenocarcinoma histology, and a history of
never smoking, although only adenocarcinoma histology p 
0.01) and a history of never smoking (p  0.001) were
significantly associated with response in a multivariate anal-
ysis. In a multivariate analysis, the factors associated with
longer survival included treatment with erlotinib p  0.002),
Asian origin p  0.01), adenocarcinoma p  0.004), and
non-smoking history p  0.0048). Analysis for predictors of
survival benefit indicated that erlotinib had a beneficial effect
in most subgroups, and the only significant factor that pre-
dicted differential survival benefit for erlotinib therapy was
smoking history. A similar survival benefit was found for
both second- and third-line patients (adjusted HR, 0.8; 95%
CI, 0.6–1.1 for both).38
The molecular analysis of tumor samples could be
attempted for only 328 of 731 study participants.44 The
analysis performed included the quantification of EGFR pro-
tein expression, estimation of EGFR gene copy number, and
sequencing of exons 18–21 to identify EGFR gene mutations,
which was successful for only 325, 125, and 177 samples,
respectively. Univariate analysis of the results suggested an
association between EGFR gene amplification/polysomy, but
not EGFR gene mutation, and the likelihood of response to
erlotinib, although EGFR expression was the only molecular
marker significantly associated with response, in a multivar-
iate analysis p  0.03). The survival of patients with EGFR-
expressing tumors (EGFR-positive), and those with EGFR
gene amplification/polysomy, was longer with erlotinib than
placebo, while survival for patients with EGFR-negative or
non-amplified tumors was not different between treatment
groups. However, neither EGFR expression nor EGFR gene
mutation or copy number were significantly associated with
survival benefit for erlotinib, in a multivariate analysis.44
The QOL analysis reported for the BR.21 trial indicated a
significant benefit for erlotinib in time to deterioration in several
patient-reported symptoms, including cough (adjusted p 
0.04), dyspnea (adjusted p  0.03), and pain (adjusted p 
0.04). Treatment with erlotinib was also associated with more
frequent improvement in overall physical function p  0.01),
overall emotional function p  0.01), and global QOL (p 
0.01), compared with placebo.45 Grade 3/4 toxicities occurred
TABLE 4. Trials of Combination Chemotherapy without Docetaxel
Reference Treatment Na
% Patientsb
Response Rate
(CRPR)d
Survival
Treatment
Line 2nd/
3rd/4th
PSc
0–1/2
Median, Months
(95% CI)
1-year
(95% CI) Overall
Randomized phase II trials
Georgoulias
2004 (35)
Irinotecan 71 100/0/0 90/10 4.2% 7 29% p  0.589 log rank
Irinotecan  Gemcitabine 76 100/0/0 91/9 18.4% 9 24.5%
p  0.009
Georgoulias
2005 (36)
Cisplatin 73 90/10/0 78/22 7.0% 8.8 31.7% p  0.934 log rank
Cisplatin  Irinotecan 74e 96/4/0 82/18 22.5% 7.8 34.3%
p  0.012
Abbreviations: CI  confidence interval, CR  complete response, N  number of patients, PR  partial response, PS  performance status.
a This column reports the number of patients randomized or randomized and eligible unless otherwise indicated.
b None of the trials reported if patients with CNS metastases were included.
c Based on the World Health Organization scale (35,36).
d 134 patients evaluable for response (36) or 147 patients evaluable for response (35).
e Seven of the 154 randomized patients were excluded from the analyses because of a major protocol violation, failure to receive study treatment, or administration of
radiotherapy.
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with similar incidence in both treatment arms, with the
exception of rash and diarrhea, which occurred more fre-
quently with erlotinib, and infection, which occurred more
frequently with placebo. Grade 3/4 pneumonitis occurred in
1% of patients in both arms.
Single-Agent Gefitinib Compared with BSC or Other
Single Agent
Two randomized trials, one phase III and one phase II,
have included comparisons involving gefitinib. The phase II
trial has been reported in abstract form only and provided
limited information regarding study design and analysis.41,42
The Iressa Survival Evaluation in Lung cancer (ISEL)
phase III trial compared the EGFR-I gefitinib at a dose of 250
mg daily against placebo.37 Treatment was continued until the
loss of clinical benefit or unacceptable toxicity. Eligible
patients had to have received one or two prior chemotherapy
regimens and be refractory to or intolerant of their latest
chemotherapy regimen. Patients were randomized in a 2:1
ratio to gefitinib versus placebo. The study was initially
powered to detect a survival difference for the subset of
patients with adenocarcinoma; however, survival for the
entire patient population was later added as a co-primary
endpoint. An exploratory analysis of tumor biomarkers was
planned. Nine hundred patient deaths were estimated to
provide 90% power to detect the anticipated survival benefit
of gefitinib in the overall population, and the analysis was
performed after 969 deaths.
The comparison of survival outcomes using the strati-
fied log-rank test revealed no significant difference for ge-
fitinib over placebo for the entire patient population (HR
0.89; 95% CI 0.77–1.02, p  0.087). Comparison for the
subgroup of patients with adenocarcinoma was also not
statistically significant (HR 0.84; 95% CI 0.68–1.03, strati-
fied log-rank p  0.089), although median survival was 6.3
months for gefitinib versus 5.4 months for placebo. Cox
regression analysis, which adjusts for the effect of multiple
predictor variables on survival, was statistically significant
for gefitinib in the entire patient population p 0.03) and the
subgroup of patients with adenocarcinoma p  0.033). Pre-
planned subgroup analyses demonstrated a significant sur-
vival benefit for gefitinib in never-smokers (HR 0.67; 95% CI
0.49–0.92) and ethnic Asian patients (HR 0.66; 95% CI
0.48–0.91).37
The QOL analysis reported for the ISEL trial revealed
a non-significant trend toward favoring gefitinib for overall
QOL p  0.068). A statistically significant benefit for ge-
fitinib was observed for change in symptom score; however,
this was too small to meet the criteria for clinical relevance.
Rash and diarrhea were the most common adverse events
with gefitinib. Grade 3/4 toxicities occurred with similar
incidence for gefitinib and placebo (30% and 27%, respec-
tively), and the frequency of ILD-like events was also similar
between the groups (1%).37
The Second-line Indication of Gefitinib in NSCLC
(SIGN) trial by Cufer et al, assigned patients to docetaxel
75 mg/m2 three-weekly or gefitinib at 250 mg daily as
second-line therapy.41,42 Treatment was continued until
disease progression or unacceptable toxicity. A total of
134 patients were enrolled, with a median follow up of 9.3
months. Symptom improvement rates were seen in 36.8%
and 26.0% of patients with gefitinib and docetaxel, respec-
tively, although no statistical analysis was reported. The
mean change in LCSS score from baseline to endpoint was
also similar for the two treatment arms. The RR for
gefitinib was comparable to that for docetaxel, and median
survival was also similar for the two arms. Similar QOL
improvement rates and changes in mean QOL score were
seen for both treatments.
Gefitinib - Dose Comparisons
Two published randomized phase II trials evaluated
gefitinib at different doses, Iressa Dose Evaluation in Ad-
vanced Lung cancer, IDEAL 140 and IDEAL 2.39 These trials
were double-blinded, of similar design, and employed ge-
fitinib at 500 mg or 250 mg daily. However, the patient
populations were distinct due to differences in ethnic mix and
study eligibility criteria.
The IDEAL 1 trial enrolled patients with recurrent or
refractory disease following one or two prior chemotherapy
regimens.40 Approximately 50% of patients enrolled were
Japanese. RR was not significantly different for the two
doses, at 18–19%, and was similar for second (18%) and
third-line therapy (20%). In responding patients, the majority
demonstrated a response by the first post-baseline assessment
at four weeks. Multivariate analysis identified three factors
correlated with tumor response, female gender p  0.017),
adenocarcinoma histology p  0.021), and prior immuno/
hormonal therapy p  0.011). Whether smoking history was
included among the variables examined is unclear. Ethnicity
(Japanese versus non-Japanese) was not predictive of re-
sponse p  0.25). Median survival and symptom and QOL
improvement were similar for the two treatment groups.
The IDEAL 2 trial enrolled patients with more ad-
vanced disease than in IDEAL 1. Patients had to have
received two or more prior chemotherapy regimens (includ-
ing both platinum and docetaxel), have progressed or expe-
rienced unacceptable toxicity with the most recent regimen,
and be symptomatic at the time of enrolment.39 RR was again
not significantly different for the two doses but was approx-
imately one half that seen in IDEAL 1 (9–12%). RR was
similar for third-line (8%), fourth-line (10%), or later treat-
ment (15%) p  0.38) but was higher for patients with
adenocarcinoma compared to other histologic subtypes (13%
versus 4%, p  0.046). Multivariate analysis identified fe-
male gender as the only factor independently predictive of
response (19% versus 3% for males, p  0.001). Symptom
improvement was observed with similar frequency in both
treatment groups and, as with IDEAL 1, occurred rapidly in
patients who benefited, with the majority experiencing im-
provement within two weeks of starting treatment.46 Similar
rates of symptom improvement were observed regardless of
the number of prior chemotherapy regimens received. QOL
analysis revealed similar improvements in Trial Outcome
Index (TOI) and Functional Assessment of Cancer Therapy–
Lung (FACT-L) total scores for both treatment groups. Ad-
verse effects generally were mild but more common with the
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500 mg gefitinib dose in both IDEAL trials, particularly for
rash and diarrhea.46
Tumor samples from a subset of patients enrolled in the
IDEAL trials (119 of a total of 416 trial participants) were
subsequently analyzed for molecular markers,47 but whether
the samples analyzed were representative of each trial popu-
lation is unclear. Samples were analyzed for EGFR gene copy
number, and by sequencing exons 18–21 to identify EGFR
gene mutations. RR was higher for tumors with EGFR mu-
tations than wild type (46% versus 10%, p  0.005) but not
different for tumors with EGFR gene amplification (29%
versus 15%, p  0.319). However, as these trials were not
placebo-controlled, inferring a true interaction among treat-
ment, EGFR mutation, and tumor response is not possible.
There was no apparent relationship between either EGFR
mutation or amplification and survival.
Other Novel Systemic Agents Compared to Other
Single Agent
Several other novel systemic agents have been tested in
the second-line or subsequent therapy of relapsed/progressive
NSCLC. These include three agents for which randomized
phase II data are currently available, specifically, the histone
deacetylase inhibitors CI-99448,49 and pivaloyloxymethyl bu-
tyrate (Pivanex®)50 and the reversible proteasome inhibitor
bortezomib (Velcade®).51,52 All three trials were reported in
abstract form only and provided limited data on the trial
methods. All three trials were industry-supported and multi-
center, one being performed in the U.S.51,52 and the others
internationally.48–50 The results are summarized in Table 6.
Other Novel Systemic Agents - Dose and Schedule
Comparisons
One industry-supported randomized phase II trial, re-
ported in abstract form, explored the dose and scheduling of
the epothilone analog BMS-247550 as second-line or subse-
quent therapy for relapsed/progressive NSCLC. Due to tox-
icity (grade 3 neuropathy), the dosage of the agent was
reduced twice through protocol amendments, from 50 mg/m2
administered three-weekly to 32 mg/m2 administered three-
weekly, versus 6 mg/m2 administered on five consecutive
days every three weeks.53,54 Only the data from the final
protocol for that study are presented in Table 6.
DISCUSSION
Single-agent docetaxel at a dose of 75 mg/m2 admin-
istered every three weeks has been shown to improve overall
survival and QOL in the treatment of recurrent or progressive
NSCLC.11,12 Prior receipt of paclitaxel did not appear to
compromise this survival benefit.13,14 Single-agent pem-
etrexed at a dose of 500 mg/m2 every three weeks has been
shown to be non-inferior to docetaxel for survival, using one
method of analysis, although a second, more exacting test of
non-inferiority was not satisfied.15 Pemetrexed was also
found to be associated with less frequent hematologic toxicity
than docetaxel, however, the QOL achieved with each agent
was not significantly different. Oral topotecan has been
shown to be non-inferior to docetaxel for one-year surviv-
al,17,18 although the trend for overall survival favored do-
cetaxel. Different toxicity profiles were seen with each agent,
however, QOL measures significantly favored docetaxel.
TABLE 6. Trials of Other Novel Systemic Agents
Reference Treatment
% Patientsb
Response Rate
(CRPR)c
Survival
Na PS 0–1/2
Median,
Months 1-year
Randomized phase II trials
Von Pawel
2002d,e (48,49)
Gemcitabine  Placebo 91 NR 3.8% 6.1 NR
Gemcitabine  CI-994 89 3.5% 6.2
Raghunadharao
2005e (50)
Pivanex®  docetaxel 288 total NR 1.8% 4.6 NR
Docetaxel 10.6% 6.4
Fanucchi 2005d
(51,52)
Bortezomib 75 NR 8% 7.4 38.7%
Docetaxel  Bortezomib 80 9% 7.8 33.1%
Randomized phase II trials – dose comparison
Vansteenkiste
2003d (53,54)
BMS-247550  1, q3 wkly 76 99/1 13% NR NR
BMS-247550  5, q3 wkly 69 f 97/3 10%
Abbreviations: CR  complete response, N  number of patients, NR  not reported, PR  partial response, PS  performance status,
q  every, wkly  weekly.
a This column reports the number of patients randomized or randomized and eligible unless otherwise indicated.
b None of the trials reported whether patients with central nervous system metastases were enrolled.
c Response rate based on randomized or eligible patients (53,54), intention-to-treat (51,52) or was not reported (50).
d Abstract.
e Neoadjuvant treatment was allowed.
f A total of 152 patients were randomized; however, data were reported for only 145 patients.
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For trials of non-inferiority, ensuring that the results
achieved reflect an equivalent efficacy of treatments, rather
than equivalent lack of efficacy, is important.55 The similarity
in survival outcomes for docetaxel in the non-inferiority trials
to the Shepherd et al (TAX 317) trial (median survival of
7.1–7.9 months, and one-year survival rates of 28.7–37%)
provides reassurance in this regard. In addition, it is important
to consider the potential impact of post-study therapy, as any
cross-over would tend to lessen the difference in survival
between treatments and increase the likelihood of declaring
non-inferiority erroneously. In the Hanna et al (JMEI) trial,
the time-to-progression for both the docetaxel and pem-
etrexed arms were comparable at 3.5 versus 3.4 months p 
0.721), respectively, which supports the therapeutic equiva-
lence of the two treatments. In the Ramlau et al (387) trial, the
time-to-progression for docetaxel was significantly longer
than for topotecan, at 13.1 versus 11.3 weeks p  0.0196),
which further supports its therapeutic superiority.
Docetaxel at a dose of 33.3–40 mg/m2 administered
weekly (for six consecutive weeks on an eight-week cycle,
three weeks on a four-week cycle, or two weeks on a
three-week cycle) was associated with significantly less neu-
tropenia than a dose of 75 mg/m2 given every three weeks, in
several phase III and phase II trials.22–24 A pooled analysis of
phase III and phase II trial data, indicates that weekly treat-
ment is not associated with poorer survival than the every
three weeks schedule. However, the improved hematologic
toxicity profile seen with the weekly schedule must be
weighed against the greater inconvenience of more frequent
chemotherapy administration. There is insufficient evidence
to recommend one weekly docetaxel schedule over another,
as no randomized trial has compared the two schedules.
Docetaxel-based combination regimens have not been
found to be superior to docetaxel alone as second-line ther-
apy. The combination of docetaxel plus SGN-15 has shown
promising activity,56 however, this requires confirmation in
an appropriately designed phase III trial. The combination of
gemcitabine plus irinotecan has also demonstrated activity
and may have a role as second-line therapy for patients
receiving docetaxel-based first-line therapy.11,13,15
The EGFR-I erlotinib, at a dose of 150 mg/day, has
been shown to increase survival and improve QOL compared
to placebo in patients who have relapsed or recurred who are
not candidates for further chemotherapy.38 In contrast, the
EGFR-I gefitinib has not been shown to improve survival
over placebo,37 although subgroup analyses suggested a sur-
vival benefit for patients who were ethnic Asians or never-
smokers.37 However, gefitinib has shown activity in two
dose-comparative phase II trials, in terms of tumor response
and relief of disease-related symptoms,39,40
Several possible explanations have been suggested for
the apparent discrepancy between the results of BR.2138 and
ISEL,37 the two placebo-controlled EFGR-I trials. One factor
may be a difference in patient population between the two
trials. Patients in the ISEL trial were required to be intolerant
of chemotherapy or to have progressed within 90 days fol-
lowing their most recent chemotherapy regimen. In addition,
the proportion of patients in the ISEL trial with progressive
disease as the best response to previous chemotherapy was
high, at approximately 39%, compared to only 28% for
BR.21. As a result, the ISEL population comprised a poorer
prognostic group, which might derive less benefit from treat-
ment. Another possible explanation is that the dosing of
gefitinib used in the ISEL trial was inadequate. In ISEL,
gefitinib was administered at 250 mg/day, well below the
maximum tolerated dose of 800 mg/day established in phase
I testing,57 whereas erlotinib was given at 150 mg/day in
BR.21, close to its maximum tolerated dose of 200 mg/day.58
However, the results of the IDEAL 1 and 2 trials, demon-
strating similar RR and survival for gefitinib at 250 mg/day
and 500 mg/day, argue against this explanation.
Exploratory analyses have suggested that some patient
subgroups may be more likely to benefit from therapy with an
EGFR-I. Female gender, adenocarcinoma histology and a
history of never smoking were associated with a higher RR to
erlotinib,38 and female gender and adenocarcinoma histology
were predictive of response to gefitinib.39,40 Of these, smok-
ing history was the only factor that predicted for a differential
survival benefit for erlotinib,38,44 whereas both smoking his-
tory and Asian ethnicity predicted survival benefit with ge-
fitinib.37 Molecular analyses have indicated that EGFR ex-
pression, but not EGFR mutation, was a predictor of response
to erlotinib,38,44 whereas EGFR mutation was associated with
a higher RR for gefitinib.47 None of the molecular markers
analyzed have been shown to be predictive of survival benefit
for either agent. Therefore, at the present time, there are no
validated clinical or molecular markers on which to base the
selection of patients for treatment with an EGFR-I.
A number of other novel agents, including histone
deacetylase inhibitors and the proteasome inhibitor bort-
ezomib, have undergone preliminary testing in the treatment
of relapsed/progressive NSCLC. Combination regimens in-
corporating the histone deacetylase inhibitors CI-994 and
pivaloyloxymethyl butyrate plus chemotherapy have not been
found to be superior to chemotherapy alone and will likely
not go forward to phase III testing. In contrast, bortezomib
has shown promise, both as a single agent and in combination
with docetaxel.51,52
Although there is no proven advantage to a specific
order of second-line and subsequent therapies, the prepon-
derance of evidence is supportive of a sequence in which
chemotherapy with docetaxel or pemetrexed is administered
second-line (in suitable patients), with erlotinib administered
third-line. Trials of docetaxel have generally included a
majority of patients receiving second-line treatment, whereas
BR.21 included only patients who were considered unsuitable
for further chemotherapy, of whom one half were treated in
third line. In addition, patients enrolled in BR.21 were al-
lowed to receive docetaxel as second-line therapy, whereas
Shepherd et al (TAX 317), Fossella et al (TAX 320) & Hanna
et al (JMEI) were conducted at a time when erlotinib was not
available for second-line use. In addition, there is a substan-
tial and consistent body of phase III data that supports the
efficacy of docetaxel as second-line therapy, while only a
single phase III trial supports the benefit of erlotinib in this
setting. In the Cufer et al (SIGN) randomized phase II trial,
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which evaluated gefitinib alongside docetaxel as second-line
therapy; the median survival was similar for both treatments.
However, this trial was not designed to compare survival
outcomes and was underpowered to test non-inferiority.
External Review of the Guideline
Feedback on a draft version of this guideline was
solicited through a mailed survey of 129 Ontario practitioners
in January 2006. Of the 60 respondents, 30 indicated that the
report was relevant to their clinical practice and provided
feedback on the draft report: 90% agreed with the draft
recommendations, and 79% indicated they would be likely to
use the guideline in their own clinical practice. The guideline
was also reviewed and approved by the PEBC Report Ap-
proval Panel and the provincial Lung DSG. Comments re-
ceived through external review were incorporated into the
final practice guideline.
Practice Guideline
Based on the evidence reviewed, the Lung DSG devel-
oped the following recommendations for adult patients with
advanced or metastatic NSCLC that has recurred or pro-
gressed following prior systemic therapy:
Y Single-agent docetaxel at a dose of 75 mg/m2 every
three weeks is recommended as second-line therapy for
patients with recurrent or progressive NSCLC and ade-
quate performance status (0–2).
Y Single-agent pemetrexed at a dose of 500 mg/m2 every
three weeks is also an option for second-line therapy of
recurrent or progressive disease, if available. This che-
motherapy should be administered with the following
vitamin supplements: oral folic acid 350–1,000 mcg
daily and intramuscular vitamin B12 1,000 mcg every
nine weeks, beginning between one to two weeks before
and continuing until three weeks after chemotherapy.
Y Oral topotecan at a dose of 2.3 mg/m2 administered day
1–5 every three weeks is not recommended for second-
line therapy of recurrent or progressive disease.
Y Docetaxel administered at a dose of 33.3–40 mg/m2 (for
six weeks on an eight-week cycle or for three weeks on
a four-week cycle) may be considered in patients at high
risk of hematologic toxicity or with a previous history of
febrile neutropenia, using the three-weekly docetaxel
schedule.
Y Combination chemotherapy (docetaxel-based or other)
is not currently recommended as second-line or subse-
quent therapy for recurrent or progressive disease.
Y Erlotinib at a dose of 150 mg/day is recommended as
third-line therapy for patients with advanced recurrent or
progressive NSCLC who maintain a good performance
status following previous platinum-based and docetaxel
(or pemetrexed) chemotherapy. Erlotinib is also an op-
tion for second-line therapy, particularly for patients
who are not candidates for chemotherapy or for those
with progression after first-line docetaxel-platinum che-
motherapy.
Y Gefitinib at a dose of 250 mg/day may be considered for
second-line and subsequent therapy only for selected
symptomatic patients who are not candidates for che-
motherapy and for whom erlotinib is not available.
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APPENDIX A. Table of Literature Search Terms Used for Electronic Databasesa
Search Categories
Database and Search Dates
MEDLINE EMBASE Cochrane
Library
1966–2005 (November) 1980–2005 (week 53) 2005, Issue 4
Disease Index terms Carcinoma, non-small-cell lung; Lung adenocarcinoma; Lung alveolus cell carcinoma; Lung cancer;
Lung carcinogenesis; Lung non-small cell cancer; Lung squamous cell carcinoma
Text words Non-small cell lung
Intervention Index terms Antineoplastic agent(s); antineoplastic protocols; antineoplastic combined chemotherapy protocols;
Drug therapy combinations; Systemic therapy, Cancer chemotherapy; Drug therapy
Text words Chemotherapy
Study Design Index terms Double-blind method; Double-blind procedure; Phase 2 clinical trial; Phase 3 clinical trial; Random
allocation; Randomized controlled trial(s); Single-blind method; Single-blind procedure; Meta
analysis; Practice guideline; Methodology; Cohort Analysis; Controlled clinical trial; Major
clinical study
Text words Randomized controlled trial; Practice Guideline; Meta-Analysis; Systematic Overview/review;
Quantitative overview/review; Data pool
Disease Stage Index terms Recurrence, Neoplasm recurrence, local; Salvage therapy; Retreatment; Cancer recurrence; Recurrent
cancer; Recurrent disease; Tumor recurrence; Relapse
Text words Previous treatment; Prior treatment; Previous chemotherapy; Prior chemotherapy; Relapse, Salvage;
Refract; Rechallenge; Retreat; Reinduct; Recurrence; Second line, Third line; Fourth line
Limits English language
a Some search terms were specific to an individual database.
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APPENDIX B: Grade 3/4 Toxicity from Epidermal Growth
Factor Receptor Inhibitors Trials
Reference
Common Grade 3 or 4 Toxicity
(>5% of Patients)
Shepherd 2005
(38) (BR.21)
Erlotinib/placebo:
Fatigue, 19%/23%
Rash, 9%/0%
Infection, 2% / 5%
Anorexia, 9%/5%
Diarrhea, 6%/1%
Discontinued due to toxicity, 5% / 2%
Toxic deaths, 1 patient/1 patient
Thatcher 2005
(37) (ISEL)
Gefitinib was generally well tolerated
Fukuoka 2003 (40)
(IDEAL 1)
Gefitinib 250 mg/Gefitinib 500 mg :
Rash, 1%/7%
Diarrhea, 0%/7%
Increased ALT, 2%/6%
ILD events, 0%/2%
Kris 2003 (39)
(IDEAL 2)
Gefitinib 250 mg/Gefitinib 500 mg:
Overall, 7%/18%, p  0.02Skin, 0%/4%
Diarrhea, 1%/ 5%
Pulmonary, 6%/7%
No ILD events Treatment-related deaths, 0%/1%
Cufer 2005
(41,42) (SIGN)
Gefitinib/Docetaxel:
Neutropenia, 2%/46%
Leukopenia, 0%/37%
Asthenic conditions, 6%/4%
Dyspnea 9%/6%
Abbreviations: ALT  alanine aminotransferase, ILD  interstitial lung disease.
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